BioCardia, Inc. (NASDAQ:BCDA) President and Chief Executive Officer Peter Altman has executed two separate purchases of the company’s common stock, totaling $1,194 in value. On January 20, 2026, Altman acquired 600 shares at prices varying from $1.31 to $1.33, resulting in an average purchase price of $1.32 per share and totaling $792. The following day, on January 21, 2026, he increased his position by buying another 300 shares, this time at prices ranging from $1.34 to $1.35 and averaging $1.34 per share, amounting to $402.
These insider transactions came at a time when BioCardia’s stock price was experiencing downward pressure, having fallen 8.57% over the prior week and down 44.23% over the last six months, according to InvestingPro data. Despite a market capitalization of approximately $13.69 million and a balance sheet with more cash than debt, the company currently holds a WEAK financial health rating. Moreover, BioCardia is rapidly depleting its available cash reserves.
InvestingPro’s analysis indicates that the stock may be modestly undervalued at present, with detailed insights accessible through their Pro Research Report which compiles over 1,400 in-depth analyses that translate complex financial data into actionable knowledge.
Following these transactions, Altman holds a direct ownership stake of 268,866 shares in BioCardia.
In company developments, BioCardia recently released its fiscal results for the third quarter of 2025, drawing particular attention to advances in its heart failure treatment pipeline. The company highlighted the CardiAmp cell therapy, which has been granted breakthrough therapy designation by the FDA, a status that could accelerate its development and regulatory review. Additionally, BioCardia emphasized its strategic initiatives centered on the Japanese market.
While net losses narrowed compared to the previous year, BioCardia continues to push forward with its innovative therapeutic programs. Leadership transitions were also announced, including the appointment of Marvin Slosman to the company’s Board of Directors, effective December 2, 2025. Slosman fills the seat previously held by Dr. Richard Krasno and currently serves as President, CEO, and Director of InspireMD.
Further strengthening the executive team, BioCardia named Farhan Shahab as Vice President of Quality. Shahab brings over 25 years of experience, most recently from Welldoc, where he held a senior role.
These personnel updates and ongoing clinical developments reflect BioCardia’s dedication to reinforcing its management capabilities and advancing its cardiac therapeutic offerings amid a challenging financial environment.